ReviewJournal of experimental & clinical cancer research : CR2026
Recapitulating the tumour microenvironment: advancing personalised radiation therapy through organoid technology.
Review in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The efficacy and resistance of tumor radiotherapy are profoundly influenced by the complex tumor microenvironment (TME). However, traditional preclinical models have limitations in accurately simulating the heterogeneity and dynamic interactions of the human TME, hindering the development of TME-targeted radiosensitization strategies. Organoid technology, as a revolutionary three-dimensional in vitro model, faithfully recapitulates the histological architecture, cellular diversity, and genetic characteristics of primary tumors. This provides a powerful platform for investigating the impact of the TME on radiotherapy response within a system that highly mimics physiological/pathological conditions. This review systematically elaborates on how organoid technology guides tumor radiotherapy by modeling key components of the TME. We begin by outlining the features of organoid technology and its advantages in recapitulating TME heterogeneity. Subsequently, we delve into the latest applications of organoid models in deciphering how key factors within the TME—such as cell-cell interactions, immune cell functions, stromal components, and hypoxic conditions—influence radiotherapy response. Furthermore, this article summarizes the progress in using organoid technology to study radiosensitivity across different tumor types and highlights its great potential, particularly when integrated with multi-omics technologies, for uncovering mechanisms of radiotherapy resistance. Based on this research, we emphasize the clinical translation prospects of organoid technology as a functional platform for guiding personalized radiotherapy strategies, including dose screening and combination therapy. Finally, we objectively discuss the current technical challenges faced by these models, including standardization, vascularization, immunocompetence, and clinical integration, and offer perspectives on future optimization directions and their broad clinical application potential. In conclusion, organoid technology holds promise for reshaping the research paradigm of tumor radiotherapy and advancing the era of individualized precision radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.